PBIT is a potent, selective inhibitor of KDM5B that reduces the expression of JARID1B, which results in decreased levels of cancer stem cell (CSC) and epithelial-mesenchymal transition (EMT) markers in cisplatin-resistant non-small cell lung cancer (229). This evidence concerns the gene KDM5B and non-small cell lung carcinoma.